SG Americas Securities LLC Has $379,000 Stock Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

SG Americas Securities LLC boosted its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 36.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,452 shares of the company’s stock after purchasing an additional 4,626 shares during the quarter. SG Americas Securities LLC owned 0.06% of Fulgent Genetics worth $379,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of FLGT. Asset Dedication LLC bought a new stake in shares of Fulgent Genetics in the second quarter worth about $33,000. nVerses Capital LLC acquired a new position in shares of Fulgent Genetics in the 2nd quarter valued at approximately $43,000. Signaturefd LLC increased its stake in Fulgent Genetics by 103.6% during the 2nd quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after purchasing an additional 1,132 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Fulgent Genetics during the 2nd quarter worth approximately $63,000. Finally, State Board of Administration of Florida Retirement System bought a new position in Fulgent Genetics in the first quarter valued at approximately $178,000. Institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Stock Up 0.5 %

Shares of FLGT stock opened at $19.76 on Friday. Fulgent Genetics, Inc. has a 12-month low of $18.91 and a 12-month high of $30.68. The firm has a fifty day moving average of $21.86 and a 200-day moving average of $21.48. The company has a market capitalization of $591.30 million, a price-to-earnings ratio of -3.55 and a beta of 1.50.

Fulgent Genetics (NASDAQ:FLGT) last released its earnings results on Friday, August 2nd. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.45. Fulgent Genetics had a negative return on equity of 2.75% and a negative net margin of 56.22%. The firm had revenue of $71.03 million during the quarter, compared to analysts’ expectations of $69.07 million. During the same quarter in the prior year, the company earned ($0.33) EPS. The company’s revenue was up 4.7% on a year-over-year basis. On average, equities analysts expect that Fulgent Genetics, Inc. will post -1.46 EPS for the current year.

Insider Buying and Selling

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,313 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total value of $52,805.79. Following the sale, the chief executive officer now owns 707,275 shares in the company, valued at approximately $16,147,088.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 4,324 shares of company stock worth $98,717. 31.76% of the stock is owned by corporate insiders.

About Fulgent Genetics

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.